SLCO2B1 and prostate carcinoma: Abiraterone inhibits CYP17A, blocking the conversion of pregnenolone to DHEAS precursors, decreasing adrenal androgen biosynthesis.44 Abiraterone also enters prostate cancer cells through SLCO2B1 to elicit intraprostatic antineoplastic effects.45 Thus, statins and abiraterone may work together to lower circulating and intraprostatic DHEAS levels.